<code id='196B96D5A8'></code><style id='196B96D5A8'></style>
    • <acronym id='196B96D5A8'></acronym>
      <center id='196B96D5A8'><center id='196B96D5A8'><tfoot id='196B96D5A8'></tfoot></center><abbr id='196B96D5A8'><dir id='196B96D5A8'><tfoot id='196B96D5A8'></tfoot><noframes id='196B96D5A8'>

    • <optgroup id='196B96D5A8'><strike id='196B96D5A8'><sup id='196B96D5A8'></sup></strike><code id='196B96D5A8'></code></optgroup>
        1. <b id='196B96D5A8'><label id='196B96D5A8'><select id='196B96D5A8'><dt id='196B96D5A8'><span id='196B96D5A8'></span></dt></select></label></b><u id='196B96D5A8'></u>
          <i id='196B96D5A8'><strike id='196B96D5A8'><tt id='196B96D5A8'><pre id='196B96D5A8'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:hotspot    - browse:923

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia